Quzyttir (Cetirizine HCl) Patent Expiration, LOE Window & CMS Spending
Quzyttir (Cetirizine HCl) by Esteve Sa: FDA Orange Book LOE 2030-02-28, 0 AB generics, $638K 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Esteve Sa |
| FDA Application & Pathway | N211415 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-02-28 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $638K |
| 2024 Medicare Part D Spend | $638K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 25.2% 2-yr change) |